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The effect of ZD1839 (‘Iressa’), a speciﬁc inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor, on
the radiation response of human tumour cells (LoVo colorectal carcinoma) was evaluated in vitro and in vivo. ZD1839 (0.5 mM,
incubated days 1–5) signiﬁcantly increased the anti-proliferative effect of fractionated radiation treatment (2 Gy day
71, days
1–3) on LoVo cells grown in vitro (P=0.002). ZD1839 combined with either single or fractionated radiotherapy in mice
bearing LoVo tumour xenografts, also produced a highly signiﬁcant increase in tumour growth inhibition (P40.001) when
compared to treatment with either modality alone. The radio-potentiating effect of ZD1839 was more apparent when
radiation was administered in a fractionated protocol. This phenomenon may be attributed to an anti proliferative effect of
ZD1839 on tumour cell re-population between radiotherapy fractions. These data suggest radiotherapy with adjuvant
ZD1839 could enhance treatment response. Clinical investigation of ZD1839 in combination with radiotherapy is therefore
warranted.
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The epidermal growth factor receptor (EGFR) is a transmembrane
glycoprotein consisting of an external ligand binding domain, a
transmembrane domain and an intracellular tyrosine kinase
domain. EGFR activates downstream signalling pathways involved
in cell proliferation and survival, such as the Ras/Raf/MAPK and
the PI3-K/Akt pathways, in response to the binding of structurally
related ligands such as EGF and transforming growth factor a
(TGFa) (reviewed in Salomon et al, 1995). Expression or overex-
pression of EGFR is frequently observed in human cancers
including non-small cell lung cancer and hormone-refractory pros-
tate cancer (Salomon et al, 1995), and over expression has been
associated with poor prognosis in several cancer types, including
breast (Sainsbury et al, 1987), pancreas (Dong et al, 1998) and
laryngeal (Maurizi et al, 1996). This observation provided the
rationale for the development of inhibitors of the EGFR-mediated
signalling cascade as anticancer therapeutics (Ciardiello, 2000a).
ZD1839 (‘Iressa’) is an orally active, selective EGFR-TKI (epidermal
growth factor receptor-tyrosine kinase inhibitor) that blocks signal
transduction pathways implicated in the proliferation and survival
of cancer cells, and other host-dependent processes promoting
cancer growth. ZD1839 is currently in Phase III development for
non-small cell lung cancer and in Phase II clinical trials in a
number of other tumour types, and has demonstrated promising
antitumour activity with good tolerability in Phase I dose-escala-
tion studies (Baselga et al, 2000; Ferry et al, 2000). Recently, in
vitro studies have revealed that ionising radiation stimulates
EGFR-mediated MAPK activation (Schmidt-Ullrich et al, 1997).
Enhanced signalling via this pathway affords a proliferative
(Schmidt-Ullrich et al, 1997; Dent et al, 1999; Reardon et al,
1999) and survival advantage (Dent et al, 1999) in response to
radiation treatment. The purpose of the present study was to eval-
uate whether ZD1839 overcomes this resistance pathway and hence
inﬂuences the response of a human colorectal carcinoma cell line
(LoVo) to radiation treatment in vitro and when grown as tumour
xenografts in nude mice.
MATERIALS AND METHODS
Cell line details
The LoVo human colorectal carcinoma cell line was obtained from
ECACC. All cell culture reagents were obtained from Gibco BRL.
Cells were maintained in RPMI medium supplemented with 10%
foetal calf serum and 2 mM glutamine and routinely screened for
the presence of mycoplasma (Mycotect assay; Gibco BRL).
In vitro studies
The procedure used for the in vitro evaluation of ZD1839 in
combination with radiation was adapted from previously published
methods (Dent et al, 1999). Exponentially growing LoVo cells were
sub-cultured into duplicate 24-well plates (Falcon) at 5610
73 cells
per well and left for 24 h. Cells in both plates were exposed to
ZD1839 at a range of concentrations (0.05–0.5 mM) diluted from
a1 0m M stock in DMSO using pre-warmed RPMI medium. Thirty
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www.bjcancer.comminutes after drug exposure, one plate was irradiated with 2 Gy
(X-ray, delivered at a dose rate of 0.75 Gy per min) and the second
sham-irradiated. The radiation procedure was performed again 24
and 48 h later (total dose 6 Gy). Prior to the ﬁnal dose, freshly
prepared ZD1839 was applied to the plates and the plates incu-
bated for 72 h. The replenishment of medium and ZD1839, 48 h
through the 5 day period was performed to ensure consistent drug
exposure for the duration of the assay, since our preliminary
experiments with ZD1839 alone were based on a 72 h incubation
and previous experiments with ZD1839 in vitro have used drug
replenishment (Ciardiello et al, 2000b). Cell proliferation was then
analysed by MTT (3-4,5 dimethylthiazol-2, 5 diphenyl tetrazolium
bromide) assay (Carmichael et al, 1987). MTT (1 mg ml
71 in PBS)
was added to each experimental well to a ﬁnal concentration of
0.5 mg ml
71. Cells were incubated for 4 h at 378C, the MTT
containing medium was removed and 1 ml DMSO added per well.
Plates were shaken and the optical density (OD) read at 540 nm
using a multiwell plate reader (Titertek Twinreader).
In data analysis, pooled OD540nm values from replicate experi-
ments were used to determine drug or radiation effects on
proliferation. Drug-dependent growth inhibition was calculated
relative to either untreated (sham-irradiated) or radiation only
treated controls, in individual experiments, and the mean value
from 4–5 replicate experiments calculated.
Xenograft studies
Exponential phase LoVo cells were prepared at a 5610
7 per ml
concentration in serum-free RPMI medium. Xenografts were estab-
lished by the intra-dermal injection of a 0.1 ml volume of the
prepared cell stock, 1 cm from the tail base on the midline of
female nude mice (cba nu/nu) aged 8–10 weeks. Once a palpable
tumour was apparent, tumour volume was measured daily, using
calipers. Radiotherapy was administered at a dose rate of 2 Gy
per min to unanaesthetised mice restrained in polyvinyl jigs with
lead shielding and a cut away section to allow local irradiation
of the tumour by the unilateral beam (Pantac X-ray set; Sheldon
and Hill, 1977). Jigs were turned through 1808 halfway through
the radiation exposure time to provide a uniform dosing. For ethi-
cal reasons, experiments were terminated when a relative tumour
volume four times that at the initiation of therapy (RTV4) was
achieved. All procedures were carried out in accordance with the
Scientiﬁc Procedures Act 1986 by approved protocols (Home
Ofﬁce Project License number 40–1770) and with ethical commit-
tee approval. The ethical guidelines that were followed meet the
standards required by the UKCCCR guidelines (Workman et al,
1998). Initial experiments were performed to ascertain the response
of the LoVo xenograft to single-dose radiotherapy. Tumours were
irradiated at 5, 10 and 15 Gy to obtain a dose response curve
for this xenograft model. The anti-tumour effect of ZD1839 in
combination with single- and fractionated-dose radiotherapy was
addressed in two separate protocols. Tumour-bearing mice were
randomly assigned into groups to receive either ZD1839
(100 mg kg
71) or 0.5% polysorbate vehicle, once daily by oral
administration (0.1 ml per 10 g body weight) for 14 days. This
was administered alone, or combined with a single X-ray dose of
5 Gy (Protocol 1) or three multiple fractions of 2 Gy (Protocol
2) delivered at 24 h intervals. All treatments were performed on
mice bearing xenografts of 220–280 mm
3 in volume. Radiotherapy
was administered 2 h after ZD1839 or vehicle dosing. Growth
delays were calculated from the difference in time taken to achieve
RTV4 between control and treated tumours.
Statistical analyses
Mann–Whitney U or 2-tailed paired Student’s t-tests were used to
evaluate the signiﬁcance of the results obtained. Statistical analysis
was performed using SPSS for Windows (Version 8).
RESULTS
Antiproliferative effect of ZD1839 in combination with
radiation in LoVo human colorectal cancer cells treated
in vitro
Recent studies have shown that inhibition of EGFR-linked MAPK
activation can have profound effects on proliferation following
radiation treatment in vitro (Dent et al, 1999; Reardon et al,
1999). To ascertain whether inhibition of the TK activity of EGFR
using ZD1839 inﬂuences the proliferation of LoVo cells following
radiation, cells were exposed to ZD1839 continually for 6 days,
either alone, or in combination with three 2 Gy doses of radiation
administered at 24 h intervals on days 1–3 of the experiment. In
keeping with previous studies (Dent et al, 1999; Reardon et al,
1999), relative proliferation in irradiated vs sham-irradiated
controls was evaluated by MTT assay. In the sham-irradiated
controls, the doses of ZD1839 used had no signiﬁcant effect on
proliferation even at the highest concentration examined (0.5 mM;
P=0.35; Figure 1). Treatment with radiation alone (362 Gy)
reduced cell proliferation although this did not reach statistical
signiﬁcance (P=0.14). However, the combination of ZD1839 with
irradiation led to a drug dose-dependent increase in growth inhibi-
tion compared with that seen following radiation alone (Figure 1),
which was statistically signiﬁcant at 0.2 and 0.5 mM drug concentra-
tions (P=0.03 and 0.002, respectively; 2-tailed t-test).
Radiation response of LoVo cells when grown as xenografts
in nude mice
Our in vitro observations supported an evaluation of the effect of
ZD1839 on the radiation response of LoVo cells when grown as
xenografts in nude mice. Initial studies were undertaken to ascer-
tain the inherent radioresponsiveness of the LoVo xenograft
model. Tumours of size 220–280 mm
3 were irradiated at 5, 10
and 15 Gy and the time to achieve RTV4 determined following
each dose (Figure 2). The average (s.e.m.) growth delay achieved
was 5.0 (+1.2) and 18.5 (+2.2) days for the 5 and 10 Gy groups,
and more than 35 days for the group treated with 15 Gy. For the
latter group, the experiment was terminated 50 days after treat-
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Figure 1 Enhanced growth-inhibitory effect of ZD1839 when combined
with radiation in vitro. ZD1839-induced growth inhibition was examined in
the LoVo cell line with (Rx) or without (sham Rx) additional radiation treat-
ment. LoVo cells were exposed to ZD1839 for a period of 6 days, with or
without 362 Gy radiation administered on days 1–3 of drug treatment.
Cells were then treated with MTT for 4 h, lysed with DMSO and the op-
tical density (OD) of the resulting solution determined using a multi-well
plate reader. Growth inhibition normalised to the relevant control (i.e.
ZD1839 treatment alone related to sham-treated control and
ZD1839+radiation related to treatment with radiation alone) was calcu-
lated in each independent experiment. Data presented are means
(s.e.m.) from 4–5 individual experiments. *P=0.03; **P=0.02 (2-tailed
and t-test).
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tumours.
ZD1839 enhances the response of LoVo xenografts to
radiotherapy in vivo
To ascertain whether ZD1839 had any effect on the response of
LoVo tumours to single-dose radiotherapy, a 5 Gy radiation dose
was selected for use in combination with 100 mg kg
71 ZD1839.
Previous studies had demonstrated that this dose of drug adminis-
tered daily for 14 days would give approximately the same growth
delay as that achieved with 5 Gy in the LoVo xenograft model
(data not shown). The response of the LoVo xenografts to 5 Gy
plus ZD1839 was signiﬁcantly enhanced compared with that seen
with either drug or radiotherapy alone (Figure 3A,B, Table 1).
From the LoVo radiation dose response curve, the time to achieve
RTV4 for ZD1839 plus 5 Gy was equivalent to that which would be
obtained for a single dose of 8 Gy, giving a radiation dose modiﬁ-
cation factor of 1.6 for the combined therapy.
The effect of 100 mg kg
71 ZD1839 for 14 days was then evalu-
ated when combined with a fractionated radiation dosing protocol.
Again, tumours treated with three 2 Gy fractions at 24 h intervals
in combination with ZD1839 showed a signiﬁcantly better response
than those treated with radiation or drug alone (Figure 3C,D,
Table 1). This was also the case when compared with tumours trea-
ted with 2 Gy fractions for a period of 5 days.
While the doses of radiation used were too low to elicit any
normal tissue damage within the radiation ﬁeld, some body weight
losses were associated with ZD1839 treatment alone (Table 1).
Encouragingly, no signiﬁcant difference was apparent between the
weight-loss observed in mice receiving only ZD1839 and those
receiving the combined treatment (Table 1). In general, the nadir
weight was seen 7–9 days into the 14 day treatment period. In
approximately 85% of animals treated with ZD1839, with or with-
out combined irradiation, there was a gradual recovery of weight
through the remainder of the ZD1839 dosing period. The weight
of the remaining animals stabilised and then increased once drug
dosing had been stopped.
DISCUSSION
The EGFR has emerged as a key target for anticancer therapeutics.
This view has evolved through studies correlating EGFR expression
with disease progression in multiple tumour types (Sainsbury et al,
1987; Salomon et al, 1995; Maurizi et al, 1996; Dong et al, 1998)
and evidence that EGFR-inhibition can inﬂuence a diverse range
of pathways, including those involved in proliferation, reduced
apoptosis, angiogenesis and invasion (Woodburn, 1999).
Approaches to inhibit EGFR activation include the development
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Figure 2 Radiation-induced growth delay in LoVo tumour xenografts.
Localised radiotherapy was administered to tumours of size 220–280
mm
3 with ﬁve allocated per treatment group. Experiments were termi-
nated when RTV4 was achieved. The arrow on the 15 Gy data point indi-
cates that the mean time to achieve RTV4 was actually greater than 44 days
as the whole experiment was terminated 50 days after treatment, at which
point RTV4 had been achieved in only three of the ﬁve mice treated with
this dose. The data represent mean values (s.e.m.).
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Figure 3 ZD1839 improves the anti-tumour effect of both single (A and
B) and fractionated (C and D) dose radiotherapy in LoVo tumour xeno-
grafts. ZD1839 (100 mg kg day; po) or vehicle (0.5% polysorbate) was ad-
ministered for 14 days either alone or combined with a single dose of 5 Gy
(A and B) or three fractions of 2 Gy at 24 h intervals (C and D). Radiation
was administered 2 h after the ﬁrst dose of ZD1839 or vehicle and tumour
size monitored until RTV4 was achieved. A and C represent the mean size
(s.e.m.) of the tumours within each treatment group (n=7–11, see Table 1
for details), up until the point when any tumour within the treatment group
reached RTV4. The bar indicates the period of ZD1839 dosing. B and D
give a diagrammatic representation of the time taken for each
individual tumour within the treatment groups to achieve RTV4.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1157–1161of anti-EGFR antibodies (Mendelsohn, 1997 (review), Yang et al,
1999) or small molecule inhibitors of the EGFR-tyrosine kinase
(Ciardiello, 2000a), such as ZD1839.
EGFR is stimulated by a number of autocrine growth factors,
including EGF and TGFa. Recently, it has been shown that ionising
radiation stimulates EGFR activation and cellular proliferation
(Schmidt-Ullrich et al, 1997; Dent et al, 1999; Reardon et al,
1999; Todd et al, 1999) and that anti-EGFR antibody approaches
can improve tumour radiation response (Saleh et al, 1999; Bianco
et al, 2000; Milas et al, 2000). In the present study, we evaluated
the potential inﬂuence of ZD1839 on the radiation response of
the human colorectal carcinoma cell line LoVo which has moderate
levels of EGFR expression (33000 receptors per cell), and is there-
fore likely to be representative of most epithelial tumour cell lines
(Caraglia et al, 1994).
Initial in vitro studies demonstrated a clear antiproliferative
effect of ZD1839 when combined with fractionated radiation treat-
ment, using doses of ZD1839 that had no effect on cell growth
when administered alone. These ﬁndings are in accordance with
previously published studies, where radiation response was
enhanced when combined with a dominant negative inhibitor of
EGFR function (Contessa et al, 1999; Reardon et al, 1999).
A signiﬁcant increase in antitumour activity was observed when
ZD1839 was combined with radiotherapy in vivo. ZD1839 signiﬁ-
cantly enhanced the response of LoVo xenografts to both single-,
and fractionated-dose radiotherapy (P40.001, RTV4 values, Table
1). The effect of ZD1839 when combined with single-dose radio-
therapy was equivalent to that obtained using a 60% increase in
radiation dose. This dose modiﬁcation would be translated into
therapeutic gain if the normal tissue toxicities of radiation and
ZD1839 do not overlap. It compares favourably with recent studies
where radiation has been used in combination with cytotoxic
agents, for example, gemcitabine, where a dose modiﬁcation of
1.54 was achieved (Milas et al, 1999). The enhanced antitumour
effect of fractionated radiotherapy when combined with ZD1839
was even more marked, with concommitant ZD1839 administra-
tion being signiﬁcantly better than a 67% increase in total
radiation dose.
EGFR activation in response to radiation in vitro has been
shown to be biphasic (Dent et al, 1999). The secondary response
appears to be dependent on radiation-induced pro-TGFa cleavage
and autocrine action of TGFa. In vitro studies fail to demonstrate
an antiproliferative effect of EGFR inhibition (using a dominant
negative) following treatment with single doses of radiation
(Contessa et al, 1999), but demonstrate clear effects in combination
with fractionated radiation treatment, as seen in this and other
studies (Contessa et al, 1999; Reardon et al, 1999). It is conceivable
that the TGFa-mediated autocrine effects may have a greater inﬂu-
ence in vivo rather than in vitro.
The basis of the increased activity of ZD1839 when combined
with fractionated radiotherapy in tumour xenografts may result
from inhibition of EGFR-mediated accelerated re-population
between fractions. Indeed, EGFR signalling has been previously
linked with enhanced radiation-induced proliferation in cultured
cells (Schmidt-Ullrich et al, 1997). In addition, ZD1839 alone has
been previously demonstrated to have an antiproliferative effect
when administered in vitro that has been associated with the induc-
tion of programmed cell death (Ciardiello et al, 2000b).
ZD1839 was administered daily by oral dosing for a 14 day
period. Weight loss observed during the administration of
ZD1839 was not inﬂuenced by radiotherapy. In most ZD1839-trea-
ted mice (with or without additional radiotherapy), following a
nadir mid-way through the dosing period, weight was subsequently
re-gained while ZD1839 was still being administered. Previous
studies examining once-daily oral administration (days 1–5 and
8–12) of ZD1839 to nude mice bred on a NCR background, have
documented body weight losses of around 5% with 100 mg kg
71
and up to 9% with 150 mg kg
71 ZD1839 (Sirotnak et al, 2000).
The slightly greater weight losses observed in the present study
may reﬂect the greater duration of dosing and more chemo-sensi-
tive nature of the nude mice used (cba background).
These data may have important clinical implications. ZD1839 is
currently in Phase III development in non-small cell lung cancer,
and has shown good tolerability and promising antitumour activity
in Phase I studies in a variety of tumour types (Baselga et al, 2000;
Ferry et al, 2000). The results of this study would support the use
of ZD1839 in combination with radiotherapy in a clinical setting.
Elevated EGFR expression has been demonstrated in lung, breast,
head and neck, colorectal, oesophageal, prostate and pancreatic
tumours (Salomon et al, 1995), in which radiotherapy (with or
without surgery) is a primary treatment modality (DeVita et al,
1997; Yan et al, 2000). In addition, an inverse correlation between
EGFR expression and the radiation cure rates of syngeneic murine
tumours of different tissue origin has been demonstrated in precli-
nical studies (Akimoto et al, 1999). The doses of radiotherapy
examined in this study were insufﬁcient to elicit acute normal
tissue toxicity in the radiation ﬁeld. Provided there is no unaccep-
table potentiation of radiation toxicity in normal tissues, the
combination of ZD1839 with radiotherapy could signiﬁcantly
enhance treatment response. The combination may also enable
the radiotherapy dose to be reduced without diminishing curative
potential, thus limiting radiation morbidity.
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Table 1 Effect of ZD1839 combined with radiotherapy compared with
either agent alone. Mice bearing LoVo xenografts of 220–280 mm
3 were
treated with ZD1839 (100 mg kg day; po) or 0.5% polysorbate vehicle for
14 days either alone or combined with single- or fractionated-dose radio-
therapy. Radiation was administered 2 h after drug or vehicle. Fractions
were given at 24 h intervals
Mean (s.e.m.)
Nadir weight T/C time to
Treatment Number (% T0
a mean) (%
b) RTV4 (days)
Protocol 1
Vehicle 11 100 100 7.4 (0.4)
ZD1839 11 91 45 15.2 (0.4)
Vehicle+5 Gy 11 95 30 15.0 (0.6)
ZD1839+5 Gy 11 89
c 14 21.5 (0.4)
d
Protocol 2
Vehicle 7 99 100 9.8 (0.6)
ZD1839 7 89 42 14.9 (0.7)
Vehicle+362 Gy 7 96 48 17.2 (1.1)
Vehicle+562 Gy 8 92 41 21.4 (1.1)
ZD1839+362G y 8 8 7
e 18 28.5 (2.7)
f
aT0, start of treatment.
bT/C (treated/control) is the size of the treated tumours as a
per cent of the vehicle-only tumours when the ﬁrst tumour was excised in the latter
group.
cP=0.502 compared with ZD1839 alone, 2-tailed t-test.
dP50.001 compared
with vehicle +5 Gy or ZD1839 alone, 2-tailed t-test.
eP=0.353 compared with
ZD1839 alone, Mann–Whitney U-test.
fP=0.001 compared with vehicle
+362 Gy or ZD1839 alone, and P=0.007 compared with vehicle +562 Gy,
Mann–Whitney U-test. NA, not applicable.
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